NEWS
-
Hongmin Chen joins WARF Therapeutics
Chen to head biology for program aiming to produce preclinical candidates CONTACT: Jeanan Yasiri Moe Director of Strategic Communications [email protected] | (608) 960-9892 MADISON, Wis. – WARF Therapeutics, the multimillion-dollar…
-
WARF Therapeutics fall 2021 call for proposals
Program proposal deadline October 8 CONTACT: Jeanan Yasiri Moe Director of Strategic Communications [email protected] | (608) 960-9892 MADISON, Wis. – WARF Therapeutics collaborates with researchers to advance their work closer…
-
WARF Therapeutics spring 2021 call for proposals
Program proposal deadline April 5 CONTACT: Jeanan Yasiri Moe Director of Strategic Communications [email protected] | (608) 960-9892 MADISON, Wis. – WARF Therapeutics collaborates with researchers to advance their work closer…
-
WARF Therapeutics 2020 call for fall proposals
CONTACT: Jacqui Fuller, Strategic Communications and Marketing Manager [email protected] | 608.960.9881 Fall WARF Therapeutics (WT) Program Proposal Deadline: October 15 MADISON, Wis. – WARF Therapeutics encourages researchers working on a…
EVENTS
-
Fri 23April 23 @ 10:00 am - 11:00 amNew Strategies to Drug Challenging Targets by Exploiting Covalent Targeting, Beyond Rule of 5 Bitopic Ligands and Binary Pharmacology
New Strategies to Drug Challenging Targets by Exploiting Covalent Targeting, Beyond Rule of 5 Bitopic Ligands and Binary Pharmacology
The GTP-ase K-Ras represents the most frequently altered oncogene in cancer patients. Directly targeting K-Ras is difficult due to its picomolar affinity for GTP/GDP and the absence of easily identifiable…
For business questions, contact John Nagel or Rafael Diaz. If you are a PI interested in submitting your work to the program or talking through next steps, contact Jon Young. You do not need to have a patent, we are interested in talking with you about a new target early in your process.